MIRA PHARMACEUTICALS, INC. 8-K

What Happened
MIRA Pharmaceuticals, Inc. announced on an 8-K that its Compensation Committee approved, and the full Board ratified, a package of short- and long-term incentive awards for CEO Erez Aminov on December 16–17, 2025. The actions recognize 2025 performance, leadership on the strategic acquisition of SKNY Pharmaceutical, Inc., and achievement of a market-cap milestone under the CEO’s Long‑Term Incentive Plan.

Key Details

• Short-term incentive (STI) payout approved: $242,258 paid now; an additional $80,753 contingent on completion of the Company’s ongoing Phase 1 clinical study.
• Transaction advisory award for the SKNY acquisition approved: $915,000, payable in cash, equity, or a combination at the CEO’s election and subject to the 2024 Omnibus Equity Incentive Plan; any award will vest immediately upon grant.
• Long-term incentive (LTI) milestone achieved: issuance of 62,500 performance share units (PSUs) that will vest immediately.
• Compensation Committee authorized Company counsel to prepare required documentation and SEC filings related to these awards.

Why It Matters
These awards signal the board’s support for management and reward progress on the company’s 2025 objectives—clinical advancement, capital raising, and a strategic acquisition that expands the pipeline. For investors, the disclosures show cash and equity dilution potential (via equity-based awards) and indicate management incentives tied to both near-term trial milestones and longer-term market-cap performance.